For patients without driver alterations and high programmed cell death-ligand 1 (PD-L1) expression [tumor proportion score (TPS) ≥ 50%], immunotherapy has become the standard of care, as reported by updated ESMO guidelines, while a combination of chemotherapy and immunotherapy is recommended for most patients with negative or low PD-L1 expression [2]. The gene discussed is CD274; the disease is neoplasm.